Benzinga | Oct 21, 2021 12:11PM EDT

BeyondSpring Announces First Patient Treated In Phase 2 Study With Plinabulin Combined With Nivolumab + Ipilimumab In Patients In 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

--The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S.

--In the Phase 1 study, plinabulin combination was able to induce tumor responses in patients who had progressed on platinum and checkpoint inhibitors, with 43% ORR (3 partial responses with tumor reduction >50%). Duration of treatment was as long as 18 months in 1 patient.